Pan‐PI3K/mTOR inhibitors like gedatolisib inhibit critical PAM‐controlled functions more effectively than single‐node PAM inhibitors, thus achieving greater growth‐inhibitory effects in PC cells, regardless of PTEN status or androgen sensitivity. The gene discussed is PIK3CA; the disease is pachyonychia congenita.